MedTrace Logo

HEParin Antagonisation in Transcatheter Aortic Valve Implantation

NCT05422170 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2022-07-05

No results posted yet for this study

Summary

Unfractioned heparin is usually given in a defined dosage during transfemoral TAVI. Activated Clotting Time (ACT) is usually used to measure the heparin effect. ACT-analysis is easy to perform at the bedside, but susceptible to interference effects. At the end of the procedure, protamine is given to reverse eventual residual heparin effect. An overdose of protamine can impair the coagulation itself. The investigators want to analyse the effect of a partial heparin reversal by ROTEM Analysis.

Conditions

  • Aortic Valve Stenosis
  • Transcatheter Aortic Valve Implantation
  • Protamine Sulfate Overdose

Sponsors & Collaborators

  • Deutsches Herzzentrum Muenchen

    lead OTHER

Principal Investigators

  • Patrick Mayr · Deutsches Herzzentrum München

  • Michael Joner · Deutsches Herzzentrum München

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-01-31
Completion
2023-04-01

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05422170 on ClinicalTrials.gov